Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026
Company Deals

Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline

Fineline Cube Jul 9, 2026
Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Fineline Cube Jul 9, 2026
Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Fineline Cube Jul 9, 2026
Company Drug

Jiangsu Hengrui Pharmaceuticals Advances Novel Cancer Therapies with NMPA Clinical Trial Approval

Fineline Cube Jan 5, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received approval from the National Medical Products...

Company Deals

Suzhou Elite Analytical Instruments Secures Over $14 Million in Initial Funding Round

Fineline Cube Jan 5, 2024

Suzhou Elite Analytical Instruments Co., Ltd, a leading specialist in liquid chromatography based in China,...

Company Drug

Jiangsu Vcare PharmaTech Submits NDA to US FDA for Vicagrel, a P2Y12 Receptor Antagonist

Fineline Cube Jan 5, 2024

Jiangsu Vcare PharmaTech Co., Ltd, a Chinese pharmaceutical company, has submitted a New Drug Application...

Company Deals

Allorion Therapeutics and Avenzo Seal Deal for Global Rights to CDK2 Inhibitor

Fineline Cube Jan 5, 2024

China-based Allorion Therapeutics has entered into a licensing agreement with Avenzo Therapeutics Inc., granting the...

Company Drug

BMS’s Sotyktu, First TYK2 Inhibitor, Hits Chinese Market

Fineline Cube Jan 5, 2024

US pharmaceutical giant Bristol Myers Squibb (BMS, NYSE: BMY) has announced the market launch of...

Legal / IP

China’s National People’s Congress Approves Stricter Punishments for Sector-Specific Bribery

Fineline Cube Jan 4, 2024

The 7th meeting of the 14th National People’s Congress Standing Committee has passed the latest...

Company Deals Legal / IP

Daiichi Sankyo and Esperion Therapeutics Amend Collaboration on Antilipidemic Drugs

Fineline Cube Jan 4, 2024

Daiichi Sankyo (TYO: 4568)’s European subsidiary, a Japanese pharmaceutical company, has entered into a collaboration...

Company Drug

Shanghai BDgene Technology’s Thalassemia Gene Therapy BD211 Clears NMPA for Clinical Trials

Fineline Cube Jan 4, 2024

Shanghai BDgene Technology Co., Ltd, a specialist in gene therapy, has received clinical trial approval...

Company Drug

Belief BioMed Group Initiates Clinical Study for Hemophilia A Gene Therapy BBM-H803 in China

Fineline Cube Jan 4, 2024

Belief BioMed Group, a Shanghai-based gene therapy specialist, has announced the first subject dosing in...

Company Deals

IASO Biotherapeutics and Umoja Biopharma Join Forces for Innovative Cell and Gene Therapies Development

Fineline Cube Jan 4, 2024

IASO Biotherapeutics, a China-based company, and Umoja Biopharma, a California-headquartered developer of off-the-shelf cell therapies,...

Company Deals

Full-Life Technologies Secures USD 63.3 Million in Financing to Boost Radiotherapeutics Pipeline and Manufacturing

Fineline Cube Jan 4, 2024

Full-Life Technologies Ltd, a global radiotherapeutics company with a presence in Belgium, Germany, and China,...

Company Drug

Jiangsu Hengrui Pharmaceuticals Secures NMPA Approval for Abiraterone in Prostate Cancer Treatment

Fineline Cube Jan 4, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received marketing approval...

Company Drug

ImmunoTech Biopharm Commences Patient Enrollment in Phase II Study for CAR-T-19 Injection

Fineline Cube Jan 4, 2024

ImmunoTech Biopharm Ltd, a China-based specialist in chimeric antigen receptor T-cell (CAR-T) therapies (HKG: 6978),...

Company

Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer to Lead Pipeline Strategy

Fineline Cube Jan 4, 2024

Brii Biosciences Ltd (HKG: 2137), a leading biotechnology company based in China, has announced the...

Company Deals

GenScipt Subsidiary Legend Biotech Finalizes Licensing Deal with Novartis for DLL3 CAR-T Therapies

Fineline Cube Jan 4, 2024

GenScipt Biotech Corp., a China-based Contract Development and Manufacturing Organization (CDMO) (HKG: 1548), has announced...

Company Drug

Sino Biopharmaceutical Ltd Secures Exclusive Rights for Generic Everolimus in China

Fineline Cube Jan 4, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading pharmaceutical company based in China, has announced that...

Company Deals

Kexing Pharmaceutical Enters Global Licensing Agreement with Xiling Lab for Eribulin Generic

Fineline Cube Jan 4, 2024

China-based Kexing Pharmaceutical (SHA: 688136) has entered into a global licensing and supply agreement with...

Company Deals

Bio-Thera Solutions Grants Macter International Exclusive Rights to Avzivi in Pakistan and Afghanistan

Fineline Cube Jan 4, 2024

Bio-Thera Solutions (SHA: 688177), a Guangzhou-based biopharmaceutical company, has announced a licensing and commercialization agreement...

Company Deals

Boehringer Ingelheim Partners with Suzhou Ribo Life Science to Develop siRNA Therapies for NASH/MASH

Fineline Cube Jan 4, 2024

Boehringer Ingelheim (BI), a Germany-headquartered pharmaceutical company, has entered into a collaboration agreement with Suzhou...

Company Drug

Sciwind Biosciences’ Ecnolgutide Shows Promising Phase III Results in Type 2 Diabetes Treatment

Fineline Cube Jan 4, 2024

Sciwind Biosciences Co., Ltd, a China-based pharmaceutical company, has released the latest topline Phase III...

Posts pagination

1 … 447 448 449 … 693

Recent updates

  • Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients
  • Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs
  • Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial
  • Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST
  • Changchun High & New Technology’s Subsidiary GenSci Secures NMPA IND Acceptance for GenSci148, First-in-Class VEGF Multi-Blocker for Retinal Vascular Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Company Drug

Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.